Abstract: Renin–angiotensin system (RAS) inhibitors prevent the injury of cardiovascular, pancreas islet and bone tissue by inhibiting the activity of renin, angiotensin II type 1 receptor (AT1R) and angiotensin-converting enzyme(ACE). The bioactivators, such as Ang-(1-7) 、ATRAP、bradykinin and its derivatives, act as RAS inhibitor in vivo. The effective application of the edogenous and exogenous RAS inhibitors will play an important role in improving tissue lesions.

Key words: Renin-angiotensin system, Renin-angiotensin system inhibitors, Kallikrein-kinin system